Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Update on the DEFIFrance study from EHA

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, gives an update on the DEFIFrance study (NCT02851407) investigating defibrotide in patients with hepatic veno-occlusive disease (VOD) in the real-world. Overall, the study confirmed the efficacy of defibrotide for the treatment of severe VOD and showed that safety profile of this drug was similar to what was observed in clinical trials. In addition, it highlighted the importance of rapid intervention to improve the outcomes of patients suffering from this severe complication. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.